Pacira Biosciences (NASDAQ: PCRX) net income
Pacira Biosciences reported a net profit of $7.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $99.6m. Its net margin was 1.0%. Earnings per share were $0.16.
Pacira Biosciences's best year of the last 10 was fiscal 2020. The biggest drop was in fiscal 2021, −71.2%. It reported a loss in 5 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | $7.0m | — | 1.0% | $0.16 |
| 2024 | −$99.6m | −337.3% | −14.2% | −$2.15 |
| 2023 | $42.0m | +163.7% | 6.2% | $0.91 |
| 2022 | $15.9m | −62.1% | 2.4% | $0.35 |
| 2021 | $42.0m | −71.2% | 7.8% | $0.95 |
| 2020 | $145.5m | — | 33.9% | $3.41 |
| 2019 | −$11.0m | — | −2.6% | −$0.27 |
| 2018 | −$0.5m | — | −0.1% | −$0.01 |
| 2017 | −$42.6m | — | −14.9% | −$1.07 |
| 2016 | −$37.9m | — | −13.7% | −$1.02 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Pacira Biosciences net income compared with its sector
By net income for its latest fiscal year, Pacira Biosciences ranks 164th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Pacira Biosciences, 1.0%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 162nd | Artivion | $9.8m | 2.2% |
| 163rd | LifeStance Health Group | $9.7m | 0.7% |
| 164th | Pacira Biosciences | $7.0m | 1.0% |
| 165th | InfuSystem | $6.6m | 4.6% |
| 166th | MannKind | $5.9m | 1.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Pacira Biosciences
- How much did Pacira Biosciences earn in fiscal 2025?
- Pacira Biosciences reported a net profit of $7.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $99.6m.
- What are the earnings per share of Pacira Biosciences?
- They were $0.16 in fiscal 2025, compared with −$2.15 in fiscal 2024.
- What is the net margin of Pacira Biosciences?
- In fiscal 2025 its net profit was 1.0% of its revenue.
- What was the most profitable year for Pacira Biosciences?
- Of its last 10 fiscal years, fiscal 2020, with $145.5m.
- Where does Pacira Biosciences rank in its sector by net income?
- It ranks 164th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Pacira Biosciences come from?
- From the annual report (Form 10-K) that Pacira Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Pacira Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Pacira Biosciences: the Pacira Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.